DRDaniel Roshan Justin Raj

Daniel Roshan Justin Raj

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Daniel Roshan Justin Raj has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Molecular Mapping of Atherosclerotic Plaques with MALDI Mass Spectrometry Imaging

    by Dawid Leksa, Dorota Bartusik-Aebisher, Daniel Roshan Justin Raj, Angelika Myśliwiec, Alina Pietryszyn-Bilińska, Magdalena Moś, Piotr Oleś, Aleksandra Kawczyk-Krupka, David Aebisher

    Atherosclerosis develops within heterogeneous arterial plaques. Here, even closely neighbouring regions can differ substantially in biological activity and potential vulnerability to rupture and thrombosis. Through matrix-assisted laser desorption/ionisation mass spectrometry (MALDI-MS) and especially MALDI imaging, these differences within the plaque can be studied while also preserving tissue architecture. With MALDI analysis, prepared tissue sections are converted into spatial molecular maps that show the differences in plaque chemistry across the arterial wall. These maps can be used to link changes in lipids and other biomolecules to regions affected by inflammation, necrosis, calcification and thrombosis. This narrative review, supported by a structured search of PubMed and PubMed Central from database inception to 14 September 2026, critically examines MALDI-based research in atherosclerosis across a translational continuum. The evidence base centres on spatial MALDI-MSI of plaque tissue, with non-imaging MALDI and orthogonal non-MALDI studies used as complementary context. Particular attention is given to the strength of evidence supporting proposed molecular signatures and to the distinction between exploratory findings and clinically validated applications. Integration of MALDI with histology, clinical imaging and emerging spatial-omics approaches could strengthen the biological interpretation of plaque-specific molecular signatures. However, methodological heterogeneity, incomplete molecular identification, small study populations and limited independent and prospective validation currently restrict translation into clinical practice.

  • Open Access

    The Molecular Basis and Biomarker Potential of the HIF-1α–VEGF–GLUT1 Hypoxia Axis in Laryngeal Squamous Cell Carcinoma

    by Wojciech Domka, Maciej Misiołek, Daniel Roshan Justin Raj, Dorota Bartusik-Aebisher, Angelika Myśliwiec, David Aebisher

    In laryngeal squamous cell carcinoma, hypoxia plays a major role in growth, spread, and treatment resistance. HIF-1α, VEGF, and GLUT1 are three linked biomarkers that show different aspects of this response. Low oxygen can be sensed by HIF-1α, and it follows up by activating genes that help with the survival of the tumour cells. VEGF helps to form new blood vessels, while GLUT1 increases the uptake of glucose and maintains the production of energy even when there is a lack of oxygen. Tissue and serum studies have reported higher levels of these biomarkers in malignant than in benign or normal samples, together with associations with adverse clinicopathological features. However, their diagnostic and prognostic utility remains exploratory because clinically validated thresholds, diagnostic performance measures, and independent prospective validation remain limited. Combined assessment of these biomarkers may provide complementary information on hypoxic signalling, angiogenesis and metabolic adaptation, although its diagnostic or prognostic superiority over individual biomarkers has not yet been established. However, serum measurements can be influenced by pre-analytical and systemic factors. So, in order for these biomarkers to advance enough to be used in clinical laryngology, large multicenter studies and a standardized set of testing methods will be necessary.

  • Open Access

    Heating the Cold: Overcoming Immunotherapy Resistance in Microsatellite-Stable Colorectal Cancer: A Systematic Review

    by Dorota Bartusik-Aebisher, Daniel Roshan Justin Raj, Izabella Wilk, David Aebisher

    Colorectal cancer (CRC) has shown significant heterogeneity regarding its response to immunotherapy. Long-lasting, beneficial effects have been observed in mismatch repair-deficient, microsatellite instability-high (dMMR/MSI-H) tumours, while mismatch repair-proficient, microsatellite stable (pMMR/MSS) tumours have remained resistant. Such differences in results have been studied in this review through the “hot” and “cold” tumour concept. It explains how various biological and microenvironmental factors play a role in immune resistance and T-cell priming and infiltration. Key factors include a low neoantigen load and defects in antigen presentation, which reduce the overall immune recognition of tumour cells. The review also studies certain processes such as Wnt/β-catenin and mitogen-activated protein kinase (MAPK) signalling and what input they have in the prevention of effective antitumour immune responses. Conventional treatments like chemotherapy and radiotherapy have been considered alongside more targeted treatments such as the inhibition of vascular endothelial growth factor (VEGF) signalling and the suppression of myeloid-mediated immune evasion, to convert “cold” MSS tumours into immune-responsive lesions. Methods which aim to modify the tumour microenvironment such as metabolic reprogramming and microbiome modulation have also been covered in this review. Artificial intelligence and nanomedicine are new technologies that could provide improved patient stratification and therapeutic precision, although their clinical application in pMMR/MSS CRC remains under investigation. A systematic literature search of PubMed and PubMed Central (PMC) was conducted from 10 June 2026 to 19 August 2026 using predefined eligibility criteria, with study selection reported according to PRISMA 2020. Because of substantial heterogeneity in study design, therapeutic approach and reported outcomes, the included evidence was synthesized narratively rather than by meta-analysis. A total of 158 studies were included.


  • Open Access

    Nanomaterial-Based Therapeutic Delivery: Integrating Redox Biology, Genetic Engineering, and Imaging-Guided Treatment

    by Dorota Bartusik-Aebisher, Daniel Roshan Justin Raj, David Aebisher

    Nanomaterials are emerging versatile platforms for therapeutic delivery, as they offer precise control over drug, antioxidant, and genetic payload transport across biological barriers. Inorganic, organic, hybrid, and biomimetic systems are the major classes of nanomaterials, which all have different physicochemical properties such as size, surface charge, and surface functionalization. These properties collectively influence stability, biodistribution, cellular uptake, and release kinetics. Engineering strategies are increasingly using stimuli-responsive designs that are triggered by pH, reactive oxygen species (ROS), and intracellular redox gradients to perform spatially and temporally controlled delivery. Antioxidant and redox-modulating nanocarriers are of great importance as they overcome the limited bioavailability and nonspecific activity of conventional antioxidants by improving stability, targeting oxidative microenvironments, and allowing for regulated release. Improvements in lipid, polymeric, and inorganic nanoplatforms have also developed gene delivery applications, including siRNA, mRNA, and CRISPR/Cas systems, to provide better cytosolic release and precise therapeutics. When diagnostic imaging is integrated with therapy through theranostic nanoparticles, real-time monitoring and personalized intervention are possible. Safety, scalable manufacturing, and regulatory alignment are some challenges that show the need for standardization and translational procedures to utilize the potential of theranostic nanomedicine.


  • Top Cited Papers
    Open Access

    Artificial Intelligence in Medical Diagnostics: Foundations, Clinical Applications, and Future Directions

    by Dorota Bartusik-Aebisher, Daniel Roshan Justin Raj, David Aebisher

    Artificial intelligence (AI) is rapidly transforming medical diagnostics by allowing for early, accurate, and data-driven clinical decision-making. This review provides an overview of how machine learning (ML), deep learning, and emerging multimodal foundation models have been used in diagnostic procedures across imaging, pathology, molecular analysis, physiological monitoring, and electronic health record (EHR)-integrated decision-support systems. We have discussed the basic computational foundations of supervised, unsupervised, and reinforcement learning and have also shown the importance of data curation, validation metrics, interpretability methods, and feature engineering. The use of AI in many different applications has shown that it can find abnormalities and integrate some features from multi-omics and imaging, which has shown improvements in prognostic modeling. However, concerns about data heterogeneity, model drift, bias, and strict regulatory guidelines still remain and are yet to be addressed in this field. Looking forward, future advancements in federated learning, generative AI, and low-resource diagnostics will pave the way for adaptable and globally accessible AI-assisted diagnostics.


  • Open Access

    Detection of Protein and Metabolites in Cancer Analyses by MALDI 2000–2025

    by Dorota Bartusik-Aebisher, Daniel Roshan Justin Raj, David Aebisher

    Cancer metabolomics has become a powerful way of understanding tumor biology, identifying biomarkers and metabolites, and helping precision oncology. Matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS), among many other analytical platforms, has gained popularity over the past two and a half decades due to its unique ability of directly analyzing metabolites in tissue with spatial resolution. This review will study 2000–2025 MALDI-based strategies for cancer metabolite detection, spanning from early proof-of-concept protein profiling to the development of high-resolution MALDI-MS imaging (MALDI-MSI), which is capable of mapping thousands of metabolites at near single-cell resolution. Its applications include the differentiation of tumor versus normal tissue, discovery of stage and subtype specific biomarkers, mapping of metabolic heterogeneity, and the visualization of drug metabolism in situ. Breakthrough technological milestones, such as the advanced matrices, on-tissue derivatization, MALDI-2 post-ionization, and the integration with Orbitrap or Fourier-transform ion cyclotron resonance (FT-ICR) platforms, have significantly improved the overall sensitivity, metabolite coverage, and spatial fidelity. Clinically, MALDI-MS has shown its purpose in breast, prostate, colorectal, lung, and liver cancers by providing metabolic fingerprints that are linked to tumor microenvironments, hypoxia, and therapeutic response. However, challenges such as the inclusion of matrix interface with low-mass metabolites, limited quantitation, ion suppression, and the lack of standardized procedures do not yet allow for the transition from translation to routine diagnostics. Even with these hurdles, the future of MALDI-MS in oncology remains in a good position with major advancements in multimodal imaging, machine learning-based data integration, portable sampling devices, and clinical validation studies that are pushing the field towards precision treatment.